Effects of Dapagliflozin on the Bone of Patients with CKD on Dialysis
Calcified Tissue International · 14.08.2026 · 117 (1)
DOI: 10.1007/s00223-026-01587-7 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Calcified Tissue International, online erschienen am 14.08.2026. Verfasst von Lauter E Pelepenko und 15 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Evaluation of Mineral and Bone Disorder in Nephrology (LEMON), Nephrology Division, School of Medical Sciences, University of Campinas…. Hauptthemen laut MEDLINE: Glucosides, Benzhydryl Compounds, Renal Dialysis, Renal Insufficiency, Chronic. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidade Estadual De Campinas.
Abstract (Originalsprache)
The effects of gliflozins on bones of CKD patients on dialysis are unknown. Recently, SGLT2 expression in bone tissue of patients with CKD has been reported. We hypothesized that dapagliflozin may act in bone cells and modulate the Klotho-FGF23 axis. This study analyzed the effects of dapagliflozin on serum bone biomarkers and related outcomes. In this predefined post-hoc analysis of a previous RCT, patients on dialysis received (1:1) dapagliflozin 10 mg daily or standard care for 24 weeks. The primary endpoint was the change from baseline in serum Klotho and FGF23 levels, compared by ranked analysis of covariance, adjusted by baseline. Exploratory analyses evaluated calcium, phosphate, PTH, bone-ALP, TRAP-5b, DKK1, sclerostin, and bone proteins. Bone fractures, osteopenia, and osteoporosis were outcomes of interest. Seventy-nine patients were included in this analysis (Control N=40 and Dapagliflozin N=39). At baseline, no significant differences in biomarkers were observed. The prevalence of osteopenia and osteoporosis was 73% and 43% ( p = 0.60 and p = 1.00), respectively. After 24 weeks, the between-group analysis of the change from baseline (delta), adjusted by baseline, revealed a significant difference in serum Klotho [19.1 (− 38.9–86.3) pg/mL, Control group; − 29.1 (− 94.1–43.9) pg/mL, Dapagliflozin group (F:4.946, p = 0.03)], but not on FGF23 levels, nor other biomarkers. The follow-up prevalences of osteopenia and osteoporosis were 70% and 48% ( p = 0.27 and p = 0.61, respectively). No bone fractures were observed. Dapagliflozin use over 24 weeks in patients on dialysis was independently associated with lowered serum Klotho levels, without effects in other bone biomarkers or related outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory for Evaluation of Mineral and Bone Disorder in Nephrology (LEMON), Nephrology Division, School of Medical Sciences, University of Campinas (Unicamp), Rua Cinco de Junho, 350, Cidade Universitária Zeferino Vaz…
- Laboratory of Atherosclerosis and Vascular Biology, Cardiology Division, School of Medical Sciences, University of Campinas (Unicamp), Campinas, Brazil.
- Growth and Development Laboratory (LabCreD), Center for Investigation in Pediatrics, School of Medical Sciences, University of Campinas (Unicamp), Campinas, Brazil.
- Laboratório de Fisiopatologia Renal (LIM 16), Nephrology Department, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), University of São Paulo (USP), São Paulo, Brazil.
- Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, TX, USA.
- MP3CV "Pathophysiological Mechanisms and Consequences of Cardiovascular Calcifications" Laboratory, UPJV UR7517, University of Picardie Jules Verne, Avenue Laennec, Amiens, France.
Förderung
- Universidade Estadual De Campinas
Zitieren
APA
Pelepenko, L. E., Barreto, J., Martins, M. P., Chiteculo, P. B., Camargo, J. M., de Oliveira, M. C., Corrêa, E. A., Pascoa, M., Guerra-Junior, G., Dominguez, W. V., Carbonara, C. E. M., Louvet, L., Moyses, R. M. A., Kuro-O, M., Sposito, A. C., & de Oliveira, R. B. (2026). Effects of Dapagliflozin on the Bone of Patients with CKD on Dialysis. Calcified Tissue International, 117(1). https://doi.org/10.1007/s00223-026-01587-7
Vancouver
Pelepenko LE, Barreto J, Martins MP, Chiteculo PB, Camargo JM, de Oliveira MC, et al. Effects of Dapagliflozin on the Bone of Patients with CKD on Dialysis. Calcified Tissue International. 2026;117(1). doi:10.1007/s00223-026-01587-7
BibTeX
@article{Pelepenko2026,
author = {Pelepenko, Lauter E and Barreto, Joaquim and Martins, Marília P and Chiteculo, Pedro B and Camargo, Jessica M and de Oliveira, Mariana C and Corrêa, Eric A and Pascoa, Mauro and Guerra-Junior, Gil and Dominguez, Wagner Vasques and Carbonara, Cinthia E M and Louvet, Loïc and Moyses, Rosa M A and Kuro-O, Makoto and Sposito, Andrei C and de Oliveira, Rodrigo Bueno},
title = {Effects of Dapagliflozin on the Bone of Patients with CKD on Dialysis},
journal = {Calcified Tissue International},
year = {2026},
volume = {117},
number = {1},
doi = {10.1007/s00223-026-01587-7}
}
EUVIMED